Overview
The marketing authorisation for Onduarp has been withdrawn at the request of the marketing-authorisation holder.
Onduarp : EPAR - Summary for the public
English (EN) (522.95 KB - PDF)
български (BG) (630.81 KB - PDF)
español (ES) (540.23 KB - PDF)
čeština (CS) (592.53 KB - PDF)
dansk (DA) (576.08 KB - PDF)
Deutsch (DE) (544.29 KB - PDF)
eesti keel (ET) (523.65 KB - PDF)
ελληνικά (EL) (636.8 KB - PDF)
français (FR) (525.51 KB - PDF)
italiano (IT) (525.8 KB - PDF)
latviešu valoda (LV) (599.49 KB - PDF)
lietuvių kalba (LT) (554.08 KB - PDF)
magyar (HU) (583.99 KB - PDF)
Malti (MT) (593.57 KB - PDF)
Nederlands (NL) (523.66 KB - PDF)
polski (PL) (594.97 KB - PDF)
português (PT) (523.91 KB - PDF)
română (RO) (554.71 KB - PDF)
slovenčina (SK) (589.48 KB - PDF)
slovenščina (SL) (586.59 KB - PDF)
Suomi (FI) (524.68 KB - PDF)
svenska (SV) (583.76 KB - PDF)
Product information
Onduarp : EPAR - Product Information
English (EN) (1.42 MB - PDF)
български (BG) (4.78 MB - PDF)
español (ES) (1.58 MB - PDF)
čeština (CS) (3.16 MB - PDF)
dansk (DA) (1.55 MB - PDF)
Deutsch (DE) (1.49 MB - PDF)
eesti keel (ET) (1.39 MB - PDF)
ελληνικά (EL) (5.04 MB - PDF)
français (FR) (1.5 MB - PDF)
hrvatski (HR) (1.1 MB - PDF)
íslenska (IS) (561.49 KB - PDF)
italiano (IT) (1.46 MB - PDF)
latviešu valoda (LV) (3.58 MB - PDF)
lietuvių kalba (LT) (1.81 MB - PDF)
magyar (HU) (3.15 MB - PDF)
Malti (MT) (3.35 MB - PDF)
Nederlands (NL) (1.47 MB - PDF)
norsk (NO) (580.92 KB - PDF)
polski (PL) (3.44 MB - PDF)
português (PT) (1.47 MB - PDF)
română (RO) (1.87 MB - PDF)
slovenčina (SK) (3.3 MB - PDF)
slovenščina (SL) (3.26 MB - PDF)
Suomi (FI) (1.53 MB - PDF)
svenska (SV) (1.43 MB - PDF)
Latest procedure affecting product information: WS/0236
17/02/2014
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Onduarp : EPAR - All Authorised presentations
English (EN) (476.3 KB - PDF)
български (BG) (530.2 KB - PDF)
español (ES) (476.78 KB - PDF)
čeština (CS) (511.93 KB - PDF)
dansk (DA) (487.48 KB - PDF)
Deutsch (DE) (476.11 KB - PDF)
eesti keel (ET) (476.63 KB - PDF)
ελληνικά (EL) (536.96 KB - PDF)
français (FR) (487.46 KB - PDF)
íslenska (IS) (25.81 KB - PDF)
italiano (IT) (474.03 KB - PDF)
latviešu valoda (LV) (518.12 KB - PDF)
lietuvių kalba (LT) (517.38 KB - PDF)
magyar (HU) (528.6 KB - PDF)
Malti (MT) (527.28 KB - PDF)
Nederlands (NL) (475.98 KB - PDF)
norsk (NO) (19.76 KB - PDF)
polski (PL) (507.57 KB - PDF)
português (PT) (487.82 KB - PDF)
română (RO) (515 KB - PDF)
slovenčina (SK) (512.76 KB - PDF)
slovenščina (SL) (499.61 KB - PDF)
Suomi (FI) (487.61 KB - PDF)
svenska (SV) (476.49 KB - PDF)
Product details
- Name of medicine
- Onduarp
- Active substance
- Telmisartan
- International non-proprietary name (INN) or common name
- telmisartan
- amlodipine
- Therapeutic area (MeSH)
- Hypertension
- Anatomical therapeutic chemical (ATC) code
- C09DB04
Pharmacotherapeutic group
Cardiovascular systemTherapeutic indication
Treatment of essential hypertension in adults:
Add on therapy
Onduarp is indicated in adults whose blood pressure is not adequately controlled on amlodipine.
Replacement therapy
Adult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of Onduarp containing the same component doses.
Authorisation details
- EMA product number
- EMEA/H/C/002118
- Marketing authorisation holder
- Boehringer Ingelheim International GmbH
Binger Strasse 173
D-55216 Ingelheim am Rhein
Germany - Marketing authorisation issued
- 24/11/2011
- Revision
- 2
Assessment history
Onduarp : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (576.31 KB - PDF)
CHMP post-authorisation summary of positive opinion for Onduarp
English (EN) (528.91 KB - PDF)
Onduarp : EPAR - Public assessment report
English (EN) (613.86 KB - PDF)
CHMP summary of positive opinion for Onduarp
English (EN) (509.84 KB - PDF)
News on Onduarp
More information on Onduarp
Public statement on Onduarp: Withdrawal of the marketing authorisation in the European Union
English (EN) (79.29 KB - PDF)